IMPOWER133
Regimen
- Experimental
- atezolizumab + carboplatin + etoposide
- Control
- placebo + carboplatin + etoposide
Population
Treatment-naive extensive-stage small-cell lung cancer
Key finding
mOS 12.3 vs 10.3 mo (HR 0.70, 95% CI 0.54-0.91, P=0.007); mPFS 5.2 vs 4.3 mo (HR 0.77, 95% CI 0.62-0.96, P=0.02)
Source: PMID 30280641
Timeline
Guideline citations
- NCCN SCLC (p.50)
- CSCO SCLC 2025 (p.63)⚠️ OCR source